NO20013469D0 - Fremgangsmåter for glukagonsuppresjon - Google Patents

Fremgangsmåter for glukagonsuppresjon

Info

Publication number: NO20013469D0
Authority: NO; Norway
Prior art keywords: procedures; glucagon suppression; exendin; glucagon; suppression
Prior art date: 1999-01-14

Application number

NO20013469A

Other languages

English (en)

Other versions

NO328077B1 (no

NO20013469L (no

Inventor

Andrew Young

Bronislava Gedulin

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-14

Filing date

2001-07-12

Publication date

2001-07-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013469(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-12 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2001-07-12 Publication of NO20013469D0 publication Critical patent/NO20013469D0/no

2001-09-14 Publication of NO20013469L publication Critical patent/NO20013469L/no

2009-11-23 Publication of NO328077B1 publication Critical patent/NO328077B1/no

Links

102000051325 Glucagon Human genes 0.000 title abstract 2
108060003199 Glucagon Proteins 0.000 title abstract 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
229960004666 glucagon Drugs 0.000 title abstract 2
238000000034 method Methods 0.000 title 1
230000001629 suppression Effects 0.000 title 1
239000000556 agonist Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NO20013469A 1999-01-14 2001-07-12 Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering. NO328077B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US11638099P	1999-01-14	1999-01-14
US13201799P	1999-04-30	1999-04-30
US17536500P	2000-01-10	2000-01-10
PCT/US2000/000942 WO2000041548A2 (en)	1999-01-14	2000-01-14	Methods for glucagon suppression

Publications (3)

Publication Number	Publication Date
NO20013469D0 true NO20013469D0 (no)	2001-07-12
NO20013469L NO20013469L (no)	2001-09-14
NO328077B1 NO328077B1 (no)	2009-11-23

Family

ID=27381821

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20013469A NO328077B1 (no)	1999-01-14	2001-07-12	Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering.
NO2010010C NO2010010I1 (no)	1999-01-14	2010-05-11	Exendin-4 (Exenatid)
NO2010012C NO2010012I1 (no)	1999-01-14	2010-05-20	Exennatid (Eksenatid)

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2010010C NO2010010I1 (no)	1999-01-14	2010-05-11	Exendin-4 (Exenatid)
NO2010012C NO2010012I1 (no)	1999-01-14	2010-05-20	Exennatid (Eksenatid)

Country Status (18)

Country	Link
US (3)	US6872700B1 (no)
EP (2)	EP1143989B1 (no)
JP (1)	JP2002538084A (no)
KR (2)	KR20020001719A (no)
CN (1)	CN100425284C (no)
AT (2)	ATE460942T1 (no)
AU (2)	AU770712B2 (no)
BR (1)	BRPI0007823A8 (no)
CA (1)	CA2356331C (no)
CY (1)	CY1106347T1 (no)
DE (2)	DE60044041D1 (no)
DK (1)	DK1143989T3 (no)
ES (2)	ES2278589T3 (no)
HK (1)	HK1046105A1 (no)
NO (3)	NO328077B1 (no)
NZ (1)	NZ512657A (no)
PT (1)	PT1143989E (no)
WO (1)	WO2000041548A2 (no)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT966297E (pt) *	1996-08-08	2009-03-18	Amylin Pharmaceuticals Inc	Regulação da motilidade gastrintestinal
US6703359B1 (en) *	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
KR100637433B1 (ko) *	2004-05-24	2006-10-20	삼성에스디아이 주식회사	발광 표시 장치
US7399489B2 (en)	1999-01-14	2008-07-15	Amylin Pharmaceuticals, Inc.	Exendin analog formulations
DE60044041D1 (de)	1999-01-14	2010-04-29	Amylin Pharmaceuticals Inc	Exendine zur Glucagon Suppression
US20030087820A1 (en) *	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
AU2014277804B2 (en) *	2001-07-31	2016-12-01	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Glp-1 exendin-4 peptide analogs and uses thereof
AU2002348469B2 (en) *	2001-10-18	2008-03-13	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DK1569680T3 (da) *	2002-10-22	2009-05-18	Waratah Pharmaceuticals Inc	Behandling af diabetes
WO2004050115A2 (en) *	2002-12-03	2004-06-17	Novo Nordisk A/S	Combination treatment using exendin-4 and thiazolidinediones
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
HRP20050683A2 (en) *	2003-03-19	2006-07-31	Eli Lilly And Company	Polyethylene glycol linked glp-1 compounds
RU2006131046A (ru) *	2004-01-30	2008-03-10	Уэрейта Фармасьютикалз, Инк. (Ca)	Совместное применение агониста glp-1 и соединений гастрина
CA2564031A1 (en) *	2004-04-23	2005-11-03	Conjuchem Biotechnologies Inc.	Method for the purification of albumin conjugates
CA2572770A1 (en) *	2004-07-08	2006-01-19	Novo-Nordisk A/S	Polypeptide protracting tags comprising a tetrazole moiety
US7393827B2 (en) *	2004-12-30	2008-07-01	Diakine Therapeutics, Inc.	Pharmaceutical compositions and methods for restoring β-cell mass and function
US8716221B2 (en) *	2005-01-14	2014-05-06	Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.	Modified exendins and uses thereof
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006099288A2 (en) *	2005-03-11	2006-09-21	Indevus Pharmaceuticals, Inc.	Controlled release formulations of octreotide
US7759312B2 (en) *	2005-03-11	2010-07-20	Endo Pharmaceuticals Solutions Inc.	Delivery of dry formulations of octreotide
LT3524261T (lt)	2005-08-19	2024-04-10	Amylin Pharmaceuticals, Llc	Eksendino naudojimas diabeto gydymui ir kūno svorio mažinimui
US8039432B2 (en) *	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007075534A2 (en)	2005-12-16	2007-07-05	Nektar Therapeutics Al, Corporation	Polymer conjugates of glp-1
CN101384623B (zh) *	2005-12-22	2013-07-24	常山凯捷健生物药物研发（河北）有限公司	白蛋白与治疗剂的预成型偶联物的制备方法
CA2651855C (en)	2006-05-30	2011-08-02	Intarcia Therapeutics, Inc.	Two-piece, internal-channel osmotic delivery system flow modulator
WO2008021133A2 (en)	2006-08-09	2008-02-21	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
CN101125207B (zh) *	2006-11-14	2012-09-05	上海华谊生物技术有限公司	带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
KR100805208B1 (ko) *	2007-03-27	2008-02-21	주식회사 펩트론	엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
ES2402172T3 (es) *	2007-04-23	2013-04-29	Intarcia Therapeutics, Inc	Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
KR20100058550A (ko) *	2007-09-11	2010-06-03	몬도바이오테크 래보래토리즈 아게	녹농균 감염 치료시 치료제로서의 밴드 ３ 단백질 （８２４－８２９） 및／또는 멜라닌세포－자극 호르몬 방출－저해 인자의 용도
CA2708762A1 (en) *	2007-12-11	2009-06-18	Conjuchem Biotechnologies Inc.	Formulation of insulinotropic peptide conjugates
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2303313B1 (en)	2008-05-21	2015-10-28	Amylin Pharmaceuticals, LLC	Exendins to lower cholestrol and triglycerides
KR20110025974A (ko)	2008-06-25	2011-03-14	엔도 파마슈티컬즈, 솔루션스 아이엔씨.	이형제를 함유하는 옥트레오티드 이식물
US8071537B2 (en) *	2008-06-25	2011-12-06	Endo Pharmaceuticals Solutions Inc.	Implantable device for the sustained release of a polypeptide
PL2341905T5 (pl)	2008-09-04	2024-01-15	Amylin Pharmaceuticals, Llc	Preparaty o przedłużonym uwalnianiu z wykorzystaniem niewodnych nośników
CN101870728A (zh)	2009-04-23	2010-10-27	派格生物医药(苏州)有限公司	新型Exendin变体及其缀合物
WO2010138671A1 (en)	2009-05-28	2010-12-02	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist compounds for sleep enhancement
KR101112578B1 (ko) *	2009-07-16	2012-02-16	성균관대학교산학협력단	엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
CN101987868B (zh) *	2009-07-30	2013-09-04	江苏豪森医药集团有限公司	Glp-1类似物的衍生物或其可药用盐和用途
LT2462246T (lt)	2009-09-28	2017-11-27	Intarcia Therapeutics, Inc	Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
KR20120116942A (ko)	2009-11-23	2012-10-23	아밀린 파마슈티칼스, 인크.	폴리펩티드 접합체
BR112012012945A2 (pt)	2009-11-25	2020-12-29	Arisgen Sa	Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
KR20130098873A (ko)	2010-04-27	2013-09-05	질랜드 파마 에이/에스	Glp-1 수용체 작용제 및 가스트린의 펩타이드 접합체 및 그의 용도
CN106986940A (zh)	2010-09-28	2017-07-28	艾米琳制药有限责任公司	具有增强的作用持续时间的工程化多肽
EA032917B1 (ru)	2010-09-28	2019-08-30	Амилин Фармасьютикалс, Ллк	Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
WO2012088157A2 (en)	2010-12-22	2012-06-28	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonists for islet cell transplantation
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714069A4 (en)	2011-05-25	2015-06-24	Amylin Pharmaceuticals Llc	LONG-TERM CONJUGATES WITH TWO HORMONES
KR101357117B1 (ko) *	2011-06-28	2014-02-06	비앤엘델리팜 주식회사	폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
CN103957926B (zh)	2011-07-08	2018-07-03	安米林药品有限责任公司	具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP2729481B1 (en)	2011-07-08	2018-10-17	Amylin Pharmaceuticals, LLC	Engineered polypeptides having enhanced duration of action with reduced immunogenicity
MX2014005351A (es)	2011-11-03	2014-05-28	Zealand Pharma As	Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
US9745359B2 (en)	2012-05-18	2017-08-29	Adda Biotech Inc.	Protein and protein conjugate for diabetes treatment, and applications thereof
CA2877363A1 (en)	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
NZ704043A (en)	2012-07-23	2017-07-28	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2894765A1 (en)	2012-12-21	2014-06-26	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
HRP20181505T1 (hr)	2013-10-17	2018-11-02	Zealand Pharma A/S	Acilirani analozi glukagona
MX369770B (es)	2013-11-06	2019-11-21	Zealand Pharma As	Compuestos agonistas triples de glucagón-glp-1-gip.
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
CA2932477C (en)	2013-12-06	2023-10-10	Baikang (Suzhou) Co., Ltd	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
US10137170B2 (en)	2013-12-20	2018-11-27	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
WO2015138638A1 (en)	2014-03-11	2015-09-17	Theraly Pharmaceuticals, Inc.	Long acting trail receptor agonists for treatment of autoimmune diseases
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) *	2014-08-21	2016-01-27	Дафот Энтерпрайсис Лимитед	Пептид для лечения сахарного диабета 2-го типа и его осложнений
GB201415598D0 (en)	2014-09-03	2014-10-15	Univ Birmingham	Elavated Itercranial Pressure Treatment
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX381640B (es)	2014-10-29	2025-03-04	Zealand Pharma As	Metodos y compuestos agonistas de gip.
KR20170137198A (ko)	2015-04-16	2017-12-12	질랜드 파마 에이/에스	아실화된 글루카곤 유사체
PL3297654T3 (pl)	2015-05-22	2021-12-20	The Board Of Trustees Of The Leland Stanford Junior University	Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
KR101661332B1 (ko)	2015-05-28	2016-09-29	(의료)길의료재단	글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CA2987766A1 (en)	2015-06-03	2016-12-08	Intarcia Therapeutics, Inc.	Implant placement and removal systems
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN117106085A (zh)	2015-12-23	2023-11-24	美国安进公司	使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
KR102508651B1 (ko)	2015-12-23	2023-03-13	더 존스 홉킨스 유니버시티	신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
HUE059737T2 (hu) *	2015-12-31	2022-12-28	Hanmi Pharm Ind Co Ltd	Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
US10653753B2 (en)	2016-03-04	2020-05-19	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
US20200164083A1 (en) *	2016-03-16	2020-05-28	Prolynx Llc	Extended release conjugates of exenatide analogs
US10501517B2 (en)	2016-05-16	2019-12-10	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
WO2018057977A1 (en)	2016-09-23	2018-03-29	Delpor, Inc.	Stable compositions for incretin mimetic compounds
SI3541366T1 (sl)	2016-11-21	2025-05-30	Amylyx Pharmaceuticals, Inc.	Zapufrane formulacije eksendina (9-39)
WO2018104263A1 (en)	2016-12-06	2018-06-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
JP7309606B2 (ja) *	2016-12-22	2023-07-18	サノフイ	活性比が最適化されたｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニスト組合せ物
IL267736B2 (en)	2017-01-03	2024-03-01	Intarcia Therapeutics Inc	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JOP20190177A1 (ar)	2017-01-17	2019-07-16	Amgen Inc	طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EP3642239A1 (en)	2017-06-20	2020-04-29	Amgen Inc.	Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja)	2017-06-21	2023-04-03	アムジエン・インコーポレーテツド	胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
WO2020185533A1 (en)	2019-03-08	2020-09-17	Amgen Inc.	Growth differentiation factor 15 combination therapy
AU2020253560B2 (en)	2019-04-05	2026-01-15	Prolynx Llc	Improved conjugation linkers
CN110151980B (zh) *	2019-06-30	2022-12-09	中国药科大学	Glp-1受体激动剂融合蛋白在制备预防或治疗高血脂药物中的应用
WO2022266467A2 (en)	2021-06-17	2022-12-22	Dana-Farber Cancer Institute, Inc.	Recombinant histone polypeptide and uses thereof
WO2024123812A1 (en)	2022-12-05	2024-06-13	Shattuck Labs, Inc.	Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US5264372A (en)	1991-03-15	1993-11-23	Amylin Pharmaceuticals, Inc.	Receptor-based screening methods for amylin agonists and antagonists
US5452284A (en) *	1992-09-14	1995-09-19	Matsushita Electric Industrial Co., Ltd.	Optical recording/reproducing medium and apparatus using land and groove encoded information signals and identification signals including position information
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2171207C (en)	1993-09-07	2010-03-30	Orville G. Kolterman	Methods for regulating gastrointestinal motility
US5726969A (en) *	1994-12-28	1998-03-10	Matsushita Electric Industrial Co., Ltd.	Optical recording medium having dual information surfaces
DE69611906T2 (de) *	1995-10-09	2001-06-21	Matsushita Electric Industrial Co., Ltd.	Optische platte mit strichkode
CN1152311C (zh) *	1995-10-09	2004-06-02	松下电器产业株式会社	光记录装置和光重放装置
US5852599A (en) *	1996-01-26	1998-12-22	Sharp Kabushiki Kaisha	Optical recording medium and optical recording/reproducing device, and manufacturing method of optical recording medium
US5883958A (en) *	1996-04-01	1999-03-16	Sony Corporation	Method and device for data decryption, a method and device for device identification, a recording medium, a method of disk production, and a method and apparatus for disk recording
US5839443A (en) *	1996-05-16	1998-11-24	The Trustees Of Columbia University In The City Of New York	Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
JP2856390B2 (ja) *	1996-07-26	1999-02-10	株式会社日立製作所	情報記録媒体及びそれを用いた記録再生方法
JP2000516912A (ja)	1996-06-05	2000-12-19	ロシュダイアグノスティクスゲゼルシャフトミットベシュレンクテルハフツング	エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
US5686511A (en)	1996-06-28	1997-11-11	The Valspar Corporation	Esterifying epoxy resin with carboxyl polymer and quenching
US6002655A (en) *	1996-07-10	1999-12-14	Hitachi, Ltd.	Optical disc apparatus accessing method and system therefor
PT966297E (pt) *	1996-08-08	2009-03-18	Amylin Pharmaceuticals Inc	Regulação da motilidade gastrintestinal
US6268343B1 (en) *	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6266299B1 (en) *	1996-12-19	2001-07-24	Matsushita Electric Industrial Co., Ltd.	Magneto-optical disk having write-once identification marks and method for recording thereof
EP0996459B1 (en)	1997-01-07	2005-09-21	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the reduction of food intake
US6051557A (en) *	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
JPH1131357A (ja) *	1997-07-08	1999-02-02	Pioneer Electron Corp	情報データの記録方法
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
NZ502592A (en)	1997-08-08	2002-03-28	Amylin Pharmaceuticals Inc	Exendin agonist peptides and their use in the treatment of type I and II diabetes
JPH11196084A (ja) *	1997-10-31	1999-07-21	Matsushita Electric Ind Co Ltd	暗号化システム
BR9814189A (pt)	1997-11-14	2000-10-03	Amylin Pharmaceuticals Inc	"compostos agonistas da exendina"
CA2310097C (en)	1997-11-14	2014-07-29	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
CA2320371C (en)	1998-02-13	2012-01-17	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and glp-1
US6376549B1 (en) *	1998-09-17	2002-04-23	Akesis Pharmaceuticals, Inc.	Metforimin-containing compositions for the treatment of diabetes
AU777564B2 (en)	1999-01-14	2004-10-21	Amylin Pharmaceuticals, Inc.	Novel exendin agonist formulations and methods of administration thereof
DE60044041D1 (de)	1999-01-14	2010-04-29	Amylin Pharmaceuticals Inc	Exendine zur Glucagon Suppression
US6451974B1 (en) *	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6519213B1 (en) *	1999-06-29	2003-02-11	Oak Technology, Inc.	Method and apparatus for reading data from a disk

2000
- 2000-01-14 DE DE60044041T patent/DE60044041D1/de not_active Expired - Lifetime
- 2000-01-14 NZ NZ512657A patent/NZ512657A/xx not_active IP Right Cessation
- 2000-01-14 JP JP2000593169A patent/JP2002538084A/ja active Pending
- 2000-01-14 ES ES00902415T patent/ES2278589T3/es not_active Expired - Lifetime
- 2000-01-14 ES ES06002683T patent/ES2343072T3/es not_active Expired - Lifetime
- 2000-01-14 KR KR1020017008892A patent/KR20020001719A/ko not_active Ceased
- 2000-01-14 EP EP00902415A patent/EP1143989B1/en not_active Expired - Lifetime
- 2000-01-14 AT AT06002683T patent/ATE460942T1/de not_active IP Right Cessation
- 2000-01-14 US US09/889,331 patent/US6872700B1/en not_active Expired - Lifetime
- 2000-01-14 DE DE60032331T patent/DE60032331T2/de not_active Expired - Lifetime
- 2000-01-14 HK HK02107813.8A patent/HK1046105A1/zh unknown
- 2000-01-14 PT PT00902415T patent/PT1143989E/pt unknown
- 2000-01-14 CN CNB008050171A patent/CN100425284C/zh not_active Expired - Lifetime
- 2000-01-14 CA CA002356331A patent/CA2356331C/en not_active Expired - Lifetime
- 2000-01-14 BR BRPI0007823A patent/BRPI0007823A8/pt not_active Application Discontinuation
- 2000-01-14 EP EP06002683A patent/EP1658856B1/en not_active Expired - Lifetime
- 2000-01-14 DK DK00902415T patent/DK1143989T3/da active
- 2000-01-14 AU AU24136/00A patent/AU770712B2/en not_active Expired
- 2000-01-14 WO PCT/US2000/000942 patent/WO2000041548A2/en not_active Ceased
- 2000-01-14 KR KR1020077009281A patent/KR20070051948A/ko not_active Ceased
- 2000-01-14 AT AT00902415T patent/ATE347901T1/de active
2001
- 2001-07-12 NO NO20013469A patent/NO328077B1/no not_active IP Right Cessation
2004
- 2004-05-26 AU AU2004202293A patent/AU2004202293B2/en not_active Expired
2005
- 2005-03-18 US US11/083,730 patent/US7153825B2/en not_active Expired - Lifetime
2006
- 2006-10-19 US US11/584,114 patent/US7407932B2/en not_active Expired - Fee Related
2007
- 2007-03-01 CY CY20071100286T patent/CY1106347T1/el unknown
2010
- 2010-05-11 NO NO2010010C patent/NO2010010I1/no not_active Application Discontinuation
- 2010-05-20 NO NO2010012C patent/NO2010012I1/no unknown

Also Published As

Publication number	Publication date
US7153825B2 (en)	2006-12-26
WO2000041548A2 (en)	2000-07-20
NO328077B1 (no)	2009-11-23
CA2356331A1 (en)	2000-07-20
ES2278589T3 (es)	2007-08-16
US6872700B1 (en)	2005-03-29
EP1143989A2 (en)	2001-10-17
EP1658856B1 (en)	2010-03-17
KR20070051948A (ko)	2007-05-18
PT1143989E (pt)	2007-03-30
KR20020001719A (ko)	2002-01-09
WO2000041548A3 (en)	2001-11-29
DK1143989T3 (da)	2007-04-16
CN1347327A (zh)	2002-05-01
CA2356331C (en)	2009-10-13
JP2002538084A (ja)	2002-11-12
ATE347901T1 (de)	2007-01-15
EP1658856A1 (en)	2006-05-24
BRPI0007823A8 (pt)	2017-03-21
NO2010012I1 (no)	2010-06-07
US20050171019A1 (en)	2005-08-04
CN100425284C (zh)	2008-10-15
US7407932B2 (en)	2008-08-05
AU2413600A (en)	2000-08-01
US20070037750A1 (en)	2007-02-15
EP1143989B1 (en)	2006-12-13
NZ512657A (en)	2004-01-30
CY1106347T1 (el)	2011-10-12
DE60044041D1 (de)	2010-04-29
ATE460942T1 (de)	2010-04-15
AU2004202293A1 (en)	2004-06-17
DE60032331T2 (de)	2007-06-21
AU770712B2 (en)	2004-02-26
AU2004202293B2 (en)	2007-09-20
BR0007823A (pt)	2001-11-20
NO20013469L (no)	2001-09-14
HK1046105A1 (zh)	2002-12-27
EP1143989A3 (en)	2002-09-11
NO2010010I1 (no)	2010-06-07
DE60032331D1 (de)	2007-01-25
ES2343072T3 (es)	2010-07-22

Publication	Publication Date	Title
NO20013469L (no)	2001-09-14	Fremgangsmåter for glukagonsuppresjon
DE60014279D1 (de)	2004-11-04	Stiftförmige Medikamentenspritze
NO20053224D0 (no)	2005-07-01	Patient controlled drug administration device.
EE200300212A (et)	2003-08-15	Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
AU2002334579A1 (en)	2003-04-14	Medical device containing light-protected therapeutic agent
AU2002342050A1 (en)	2003-04-22	Anesthesia drug monitor
NO20011721D0 (no)	2001-04-05	N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
NO20022334D0 (no)	2002-05-15	Ny sammensetning og anvendelse
DE60121988D1 (de)	2006-09-14	Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
ZA200405657B (en)	2005-08-29	Formulation & dosage form for the controlled delivery of therapeutic agents.
ATE289500T1 (de)	2005-03-15	Ophtalmologische medikamentenzuführvorrichtung
BR0311672B1 (pt)	2012-08-21	aparelho de proteção de agulha médica.
HUP0400200A3 (en)	2008-03-28	Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
ATE357928T1 (de)	2007-04-15	Pharmazeutische zusammensetzung für thrombinpeptidderivaten
AU2003293593A8 (en)	2004-05-04	Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
TR200100895T2 (tr)	2001-12-21	Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
IL159576A0 (en)	2004-06-01	Pharmaceutical formulation for the intramuscular administration of fulvestrant
NO20035602D0 (no)	2003-12-16	Sammensetning som omfatter en PDE-4-inhibitor og H1- reseptorantagonist, samt anvendelse derav til fremstilling av et medikament forbehandling av åndedrettsykdommer
IT1311921B1 (it)	2002-03-20	Composti farmaceutici.
HRP20080597T3 (en)	2008-12-31	Cancer combination therapy comprising azd2171 and zd1839
FR2820311B3 (fr)	2003-01-17	Distributeur de medicament portatif
DE69934902D1 (de)	2007-03-08	Medikament gegen drogenabhängigkeit
GB0212790D0 (en)	2002-07-10	Medicament for the treatment of diabetes
GB0201607D0 (en)	2002-03-13	Formulation for the administration of medicinal substances

Legal Events

Date	Code	Title	Description
2010-06-07	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-004/NO 20061120; FIRST REG. NO/DATE: EU , EU/1/06/362/001-004 20061120 Spc suppl protection certif: 2010010 Filing date: 20100511 Free format text: PRODUCT NAME: BYETTA; NAT. REG. NO/DATE: EU/1/06/362/001-4/NO 20061120; FIRST REG. NO/DATE: EU/1/06/362/001-004 20061120 Spc suppl protection certif: 2010012 Filing date: 20100520
2013-03-04	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA PHARMACEUTICALS LP, US
2018-02-26	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: ASTRAZENECA PHARMACEUTICALS LP, US
2020-02-10	MK1K	Patent expired